RaffaellaFaraoni Ph.D.


San Diego + 1.858.314.1153

Dr. Raffaella Faraoni focuses on the development and management of global patent portfolios in the areas of pharmaceuticals, chemicals, and biotechnology. A particular emphasis of her practice is advising clients regarding intellectual property matters for small molecule drugs, antibody-drug conjugates, and antisense oligonucleotides. Raffaella has experience assisting in opposition proceedings before the European Patent Office, IP litigation, inter partes review (IPR) proceedings, and trade secrets litigation. Raffaella advises clients on patent term extension (PTE) and Orange Book listings (approved drug products with therapeutic equivalence evaluations).

Raffaella also advises clients on due diligence matters, including providing patentability, validity, and freedom-to-operate analysis, in association with clients' investment in or acquisition of third parties, as well as licensing and collaboration opportunities. Representative clients include Merck, Bristol Myers Squibb, BioMarin Pharmaceutical, Puma Biotechnology, Genomatica, and Idenix Pharmaceuticals (a subsidiary of Merck & Co., Inc.). Raffaella counseled and assisted clients in developing patent portfolios for INGREZZA®, NERLYNX®, and AURYXIA®.

Raffaella has a Ph.D. in organic chemistry from the Swiss federal Institute of Techonolgy (ETH) and performed postdoctoral research at the Scripps Research Institute in San Diego. Her postodctorate work involved the total synthesis of natural products. Prior to joining Jones Day, Raffaella worked as a medicinal chemist at Ambit Biosciences and the Genomic Institute of the Novartis Research Foundation (GNF), where she researched the design and synthesis of kinase and ion channels small molecule inhibitors for the treatment of cancer and chronic pain. She is a coauthor of several peer-reviewed scientific articles and a co-inventor of numerous issued patents and patent applications.

Raffaella is actively involved in the Firm's pro bono initiative against human trafficking.


  • Merck resolves trade secret dispute involving vaccineJones Day represented Merck Sharp & Dohme Corp. as plaintiff in a trade secret lawsuit filed in the Eastern District of Pennsylvania against Pfizer Inc. and a former Merck employee.
  • Puma Biotechnology defends European patent licensed from Pfizer covering Neratinib extended adjuvant therapy for HER2+ breast cancer in opposition proceedingsJones Day represents Puma Biotechnology, Inc. in European opposition proceedings initiated by Hexal to defend a patent licensed from Pfizer covering Neratinib extended adjuvant therapy for HER2+ breast cancer.
  • Allergan defends JUVEDERM® patents against nine IPR petitions filed by ProlleniumJones Day is representing Allergan, Inc. before the U.S. Patent Trial and Appeal Board ("PTAB") on nine IPR petitions filed by Prollenium challenging multiple patents covering certain of Allergan's JUVEDERM® products, hyaluronic acid-based dermal fillers that include the anesthetic lidocaine.
  • BioMarin expands rare disease oligonucleotide therapeutic patent portfolio following worldwide settlement with SareptaJones Day represents BioMarin Pharmaceutical Inc. in prosecution of patent portfolio directed to oligonucleotide therapeutic agents for treatment of rare genetic diseases, including Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
  • Takeda acquires Ariad Pharmaceuticals for $5.2 billionJones Day advised Takeda Pharmaceuticals U.S.A., Inc. on intellectual property matters relating to its $5.2 billion acquisition of Ariad Pharmaceuticals.
  • Idenix establishes patent portfolio related to nucleoside analog antiviral drugsJones Day represents Idenix Pharmaceuticals, Inc. in the management and development of a patent portfolio related to nucleoside analog antiviral drugs.